Login to Your Account



Clinic Roundup


Wednesday, March 23, 2011
Cellerant Therapeutics Inc., of San Carlos, Calif., started a Phase I/II trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia. CLT-008 is an allogeneic cell-based therapy designed to provide hematopoietic support following high-dose chemotherapy or radiation exposure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription